Table 1 Clinical characteristics of nine patients with rheumatoid arthritis who developed granuloma annulare during anti-TNF therapy
PatientsAge/sexDisease duration(years)Rheumatoid factorAnti-TNF agentTime of occurrence(months)Concomitant treatmentType of skin lesionLocationOutcome
133/F16.5+Infliximab9MTX: 15 mg/weekGeneralisedHands and fingersInfliximab stopped
Prednisone: 5 mg/dayResolution
232/M8.3Infliximab6MTX 15 mg/weekGeneralisedForearmsTreatment continued
CsA: 200 mg/dayResolution
337/F17.0+Adalimumab14MTX: 15 mg/weekGeneralisedHands and forearmsTreatment continued
Resolution
476/F22.0+Adalimumab14MTX: 15 mg/weekGeneralisedHands and forearmsTreatment continued
Resolution
523/F4.0+Adalimumab4MTX: 12.5 mg/weekGeneralisedElbowsTreatment continued
Resolution
644/F20.5+Adalimumab6MTX: 12.5 mg/weekGeneralisedFingers and handsTreatment continued
Resolution
760/F17.5+Adalimumab3MTX: 15 mg/weekGeneralisedFingers, hands and forearmsAdalimumab stopped
LFN: 20 mg/dayResolution
845/F20.2+Adalimumab6MTX: 12.5 mg/weekGeneralisedForearmsTreatment continued
CsA: 150 mg/dayResolution
936/F4.7+Etanercept8MTX: 12.5 mg/weekGeneralisedFingers and handsTreatment continued
Prednisone: 5 mg/dayResolution
  • F, female; MTX, methotrexate; M, male; CsA, cyclosporin A; LFN, leflunomide; TNF, tumour necrosis factor.